Petra Weimers1, Pia Munkholm2. 1. Department of Gastroenterology, North Zealand University Hospital, Frederikssundsvej 30, 3600, Frederikssund, Denmark. malin.petra.ulfsdotter.weimers.01@regionh.dk. 2. Department of Gastroenterology, North Zealand University Hospital, Frederikssundsvej 30, 3600, Frederikssund, Denmark.
Abstract
PURPOSE OF REVIEW: Inflammatory bowel diseases (IBD), which include Crohn's disease (CD) and ulcerative colitis (UC), are chronic, relapsing diseases with unknown etiologies. The purpose of this review is to present the natural disease course evidenced in the latest epidemiology data. RECENT FINDINGS: The prevalence of IBD is rapidly increasing, affecting five million patients worldwide with the highest incidence observed in Northern Europe and Northern America. It has been shown that both CD and UC patients are at an increased risk for developing cancer of the gastrointestinal tract compared to the general population. Though the disease course of IBD is unpredictable, the rate of surgical treatment has declined potentially as a consequence of the introduction of immunomodulators and new biologic treatment options. Treatments with biological agents and/or immunosuppressive drugs as well as disease monitoring with eHealth devices seem to have a positive impact on the disease course. However, long-term follow-up studies are still lacking and therefore no reliable conclusions can be drawn as of yet. Medical compliance is paramount in the treatment of IBD, and continuous research focusing on approaches that increase compliance is also necessary.
PURPOSE OF REVIEW: Inflammatory bowel diseases (IBD), which include Crohn's disease (CD) and ulcerative colitis (UC), are chronic, relapsing diseases with unknown etiologies. The purpose of this review is to present the natural disease course evidenced in the latest epidemiology data. RECENT FINDINGS: The prevalence of IBD is rapidly increasing, affecting five million patients worldwide with the highest incidence observed in Northern Europe and Northern America. It has been shown that both CD and UC patients are at an increased risk for developing cancer of the gastrointestinal tract compared to the general population. Though the disease course of IBD is unpredictable, the rate of surgical treatment has declined potentially as a consequence of the introduction of immunomodulators and new biologic treatment options. Treatments with biological agents and/or immunosuppressive drugs as well as disease monitoring with eHealth devices seem to have a positive impact on the disease course. However, long-term follow-up studies are still lacking and therefore no reliable conclusions can be drawn as of yet. Medical compliance is paramount in the treatment of IBD, and continuous research focusing on approaches that increase compliance is also necessary.
Authors: Charles N Bernstein; Andre Wajda; Lawrence W Svenson; Adrian MacKenzie; Mieke Koehoorn; Maureen Jackson; Richard Fedorak; David Israel; James F Blanchard Journal: Am J Gastroenterol Date: 2006-07 Impact factor: 10.864
Authors: Christine Rungoe; Ebbe Langholz; Mikael Andersson; Saima Basit; Nete M Nielsen; Jan Wohlfahrt; Tine Jess Journal: Gut Date: 2013-09-20 Impact factor: 23.059
Authors: N Jewel Samadder; John F Valentine; Stephen Guthery; Harminder Singh; Charles N Bernstein; Yuan Wan; Jathine Wong; Kenneth Boucher; Lisa Pappas; Kerry Rowe; Mary Bronner; Cornelia M Ulrich; Randall W Burt; Karen Curtin; Ken R Smith Journal: Dig Dis Sci Date: 2017-01-03 Impact factor: 3.199
Authors: B Lo; M K Vester-Andersen; I Vind; M Prosberg; M Dubinsky; C A Siegel; F Bendtsen; J Burisch Journal: J Crohns Colitis Date: 2018-02-28 Impact factor: 9.071
Authors: Dessalegn Y Melesse; Lisa M Lix; Zoann Nugent; Laura E Targownik; Harminder Singh; James F Blanchard; Charles N Bernstein Journal: J Crohns Colitis Date: 2017-05-01 Impact factor: 9.071
Authors: Marley R Feitosa; Rogério S Parra; Vanessa F Machado; Gustavo N Vilar; Jussara C Aquino; José J R Rocha; Paulo G Kotze; Omar Féres Journal: Gastroenterol Res Pract Date: 2021-04-26 Impact factor: 2.260
Authors: Tamara Ortiz; Federico Argüelles-Arias; Matilde Illanes; Josefa-María García-Montes; Elena Talero; Laura Macías-García; Ana Alcudia; Victoria Vázquez-Román; Virginia Motilva; Manuel De-Miguel Journal: Nutrients Date: 2020-06-11 Impact factor: 5.717